Reply to: Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML
Journal of Clinical Oncology · 10.06.2026 · 44 (17) · 1648-1651
DOI: 10.1200/jco-26-00338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2026. Verfasst von Pau Montesinos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pau Montesinos, MD, PhD, Hospital Universitari I Politécnic La Fe, Valencia, Spain; Jorge Labrador, MD, PhD, Hospital Universitario de Burgos, Burgos…. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Pau Montesinos, MD, PhD, Hospital Universitari I Politécnic La Fe, Valencia, Spain; Jorge Labrador, MD, PhD, Hospital Universitario de Burgos, Burgos, Spain; and Pilar Lloret-Madrid, MD, Hospital Universitari I Politécn…
ORCID-Profile: Pau Montesinos, Jorge Labrador, Pilar Lloret-Madrid
Zitieren
APA
Montesinos, P., Labrador, J., & Lloret-Madrid, P. (2026). Reply to: Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML. Journal of Clinical Oncology, 44(17), 1648-1651. https://doi.org/10.1200/jco-26-00338
Vancouver
Montesinos P, Labrador J, Lloret-Madrid P. Reply to: Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML. Journal of Clinical Oncology. 2026;44(17):1648-1651. doi:10.1200/jco-26-00338
BibTeX
@article{Montesinos2026,
author = {Montesinos, Pau and Labrador, Jorge and Lloret-Madrid, Pilar},
title = {Reply to: Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {17},
pages = {1648--1651},
doi = {10.1200/jco-26-00338}
}
EUVIMED